Article
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Scientific reports - 18 May 2016
Cole Alexander J, Dwight Trisha, Gill Anthony J, Dickson Kristie-Ann, Zhu Ying, Clarkson Adele, Gard Gregory B, Maidens Jayne, Valmadre Susan, Clifton-Bligh Roderick, Marsh Deborah J
Abstract excerpt
The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian cancer (HGSOC). Mutations cause loss of wild-type p53 function due to either gain of abnormal function of mutant p53 (mutp53), or absent to low mutp53. Massively parallel sequencing (MPS) enables increased accuracy of detection of somatic variants in heterogeneous tumours. We used MPS and immunohistochemistry (IHC) to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
